

Visceral Leishmaniasis Drug Pipeline

	Phase I	Phase II	Phase III	Phase IV	Market
Impavido (Miltefosine) <small>Knight Therapeutics, Inc.</small>					■
Pentavalent antimonials					■
AmBisome <small>Gilead</small>					■
Deoxycholate					■
Paromomycin					■
Sodium stibogluconate + Paromomycin <small>DNDi; Leishmaniasis East Africa Platform</small>					■
AmBisome + Miltefosine <small>DNDi</small>					■
AmBisome + Paromomycin <small>DNDi</small>					■
Miltefosine + Paromomycin <small>DNDi</small>					■